Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease
Diabetes, Obesity and Metabolism · 2026-05 · 28 (5) · 3568-3581
DOI: 10.1111/dom.70587 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.03.2026. Verfasst von Amy K Mottl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Renal Insufficiency, Chronic, Diabetic Nephropathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer, National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM), NIHR Global Research Centre for Multiple Long Term Conditions.
Abstract (Originalsprache)
The mineralocorticoid receptor (MR) has a multifaceted role in normal physiologic functions. However, research has uncovered the deleterious consequences of overactivation of the MR. It has been implicated in chronic kidney disease (CKD) via its strong association with glomerulosclerosis, interstitial fibrosis, proteinuria, and decline in glomerular filtration rate, as well as in cardiovascular diseases through mechanisms such as excessive extracellular matrix accumulation, oxidative stress, haemodynamic changes, and sustained inflammation. As such, efforts have poured into developing therapeutic agents to inhibit the detrimental effects of MR overactivation. This narrative review describes the background to elucidating the role of MR overactivation in CKD associated with diabetes, followed by an overview of the clinical development history of MR antagonists (MRAs), initially steroidal, followed by agents with non‐steroidal structure. Clinical trials have demonstrated antiproteinuric effects of both MRA classes; however, only the non‐steroidal class has shown reductions in major adverse kidney events, with finerenone being the most widely studied. Both MRA classes also benefit heart failure and hypertension, common comorbidities in CKD, though steroidal MRAs have shown greater antihypertensive effects as well as greater risk for hyperkalaemia. This review also highlights guideline recommendations that have been developed to incorporate the latest clinical evidence, along with practical ways to manage hyperkalaemia with MRA use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- Diabetes Research Centre, Leicester Diabetes Research Centre, University of Leicester, Leicester, UK.
- Department of Endocrinology, University Hospitals Leuven-KU Leuven, Leuven, Belgium.
ORCID-Profile: Kamlesh Khunti, Chantal Mathieu
Förderung
- Bayer
- National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM)
- NIHR Global Research Centre for Multiple Long Term Conditions
- NIHR Cross NIHR Collaboration for Multiple Long Term Conditions
- NIHR Leicester Biomedical Research Centre (BRC)
- British Heart Foundation (BHF) Centre of Excellence
- National Institute for Health and Care Research
Zitieren
APA
Mottl, A. K., Khunti, K., & Mathieu, C. (2026). Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. Diabetes, Obesity and Metabolism, 28(5), 3568-3581. https://doi.org/10.1111/dom.70587
Vancouver
Mottl AK, Khunti K, Mathieu C. Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. Diabetes, Obesity and Metabolism. 2026;28(5):3568-3581. doi:10.1111/dom.70587
BibTeX
@article{Mottl2026,
author = {Mottl, Amy K and Khunti, Kamlesh and Mathieu, Chantal},
title = {Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {5},
pages = {3568--3581},
doi = {10.1111/dom.70587}
}
EUVIMED